

UNITED STATES ATOMIC ENERGY COMMISSION

COMPLIANCE INSPECTION REPORT

1. Name and address of licensee or permit holder Lakewood Hospital Nuclear Medicine Department 14519 Detroit Avenue Lakewood, Ohio	2. Date of inspection October 10, 1957
	3. Type of inspection Routine
	4. 10 CFR part(s) applicable 20 and 30

5. License (or permit) number(s) and expiration date(s)					
Number	Date	Exp. date	Number	Date	Exp. date
34-1197-1	10-1-56	10-31-58			

6. Scope of license(s) and permit
 100 millicuries Iodine 131 (iodide) for diagnosis of thyroid function. Treatment of hyperthyroidism and cardiac dysfunction.
 2 millicuries Iodine 131 (IHSA) for determination of blood volumes.
 50 millicuries Phosphorus 32 (soluble phosphate) for treatment of polycythemia vera and leukemia.

7. Special conditions and limitations of license(s) or permit
 Byproduct materials are to be used by, or under the supervision of, Dr. W. J. Fayen, at the address given above.
 Material for human use to be procured preassayed for quantity and radiochemical purity. Also to be sterilized for parenteral administration.
 Licensee to comply with 10 CFR 20 (January 29, 1957) as amended May 14, 1957.

8. Inspection findings
 Approximately 200 millicuries of Iodine 131 are procured yearly for use in diagnostic and therapeutic programs. Byproduct material is procured, as needed, in single-dose amounts from Abbott Laboratories. Instructions for nurses regarding the use of radioactive isotopes are available. Facilities and equipment are available for administering and handling byproduct material. No overexposures have been encountered. There is no waste disposal problem associated with the oral method of administration used. Dr. William J. Fayen, authorized user, is aware of the conditions of the license and 10 CFR 20, including the amendment concerning incidents.

9. Items of noncompliance
None.

10. Give date of last previous inspection: **None.**

11. Is "Company Confidential" information contained in this report? **No.**
 (Specify page(s) and paragraph(s))

DISTRIBUTION:

Dr. Marvin M. Mann
 Division of Inspection
 Washington, D. C. (2 cys)

EJM
 Eugene J. Moretti
 (Inspector)
 Approved by: [Signature]
 Roy C. Hageman, Director
 Inspection Division, COO
 (Operations office)

October 11, 1957

(Date report prepared)

If additional space is required for any numbered item above, the continuation may be extended to the reverse of this form using foot to head format, leaving sufficient margin at top for binding, identifying each item by number and noting "Continued" on the face of form under appropriate item.

RECOMMENDATIONS SHOULD BE SET FORTH IN A SEPARATE COVERING MEMORANDUM

October 10, 1957

DETAILS

12. E. J. Oparka, Inspection Division, Chicago Operations Office, accompanied the inspector.

13. Dr. W. J. Fayen, authorized user, was interviewed.

14. Organization

Dr. W. J. Fayen directly supervises the Nuclear Medicine Department of the hospital. He is the sole user of byproduct material in clinical diagnosis and therapy work. He is also directly responsible for the Nuclear Medicine Department in the St. John's Hospital, Cleveland, Ohio, where he is authorized to use byproduct material under License 34-869-1.

Dr. Fayen has had two years' experience in handling byproduct material while engaged in diagnostic and therapy programs at the Grile Veterans Administration Hospital, Cleveland Clinic, and St. John's Hospital, all in Cleveland, Ohio.

The hospital has an active isotope committee which meets periodically to supervise and review the Radioisotope Laboratory operations.

The Isotope Committee is composed of the following members:

Thomas W. Knickerbocker, M.D.
Chief, Division of Radiology, Chairman
James T. Ledman, M.D.
Chief, Division of Medicine
Helen R. Cash, M.D.
Board Qualified in Internal Medicine
Oliver Eitzen, M.D.
Chief, Division of Pathology

The Medical Staff of Lakewood Hospital has placed Dr. T. W. Knickerbocker, Radiologist, in charge of radiological safety throughout the hospital.

Written administrative instructions regarding the use of radioactive isotopes are available for nurses.

15. Scope of Work

Approximately 200 millicuries of Iodine 131 are procured yearly for use in diagnosis of thyroid function and treatment of hyperthyroidism and heart conditions.

The byproduct material program has been limited to the use of Iodine 131, to date, and is as follows:

<u>Radioisotope</u>	<u>Program</u>	<u>Cases</u>	<u>Total Amount</u>
Iodine 131	Diagnostic	260	13 millicuries
Iodine 131	Therapeutic	13	184 millicuries

The program administers to both inpatients and outpatients. Approximately 50% of the program is devoted to outpatients.

16. Facilities and Equipment

The Nuclear Medicine Department is located on the second floor of the hospital. The isotope Laboratory is a 24' x 30' room equipped with byproduct material handling and storage equipment. Radiation warning signs are posted in the Radioisotope Laboratory.

October 10, 1957

16. Facilities and Equipment (continued)

The following radiation measuring and monitoring devices were available:

Tracerlab	SC-33	Scaler
Tracerlab	P-20 AM	Scintillation Probe
Tracerlab	P-20 AN	Well Counter
Jordan	AGB-LOK-SR	Portable Laboratory Monitor
Victoreen	541 A	Pocket Dosimeter

17. Records

Material control is effected by maintaining purchase and disposition records. A single therapeutic dose of 7 millicuries of Iodine 131 was on hand, in preparation for administering to a patient the next day. No inventory is maintained.

Background and area surveys are reflected in the patient uptake study records.

Area surveys are performed after each therapeutic treatment.

No overexposures have been encountered in this program.

18. Waste Disposal

Unused 50-microcurie diagnostic capsules, if any, are stored in original shipping containers behind a lead brick shield until decayed to 5 microcuries or less, then disposed to the sewer.